| Titre |
A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours |
| Protocole ID |
Beamion PANTUMOR-1 |
| ClinicalTrials.gov ID |
NCT06581432 |
| Type(s) de cancer |
Tumeurs solides |
| Phase |
Phase II |
| Type étude |
Clinique |
| Médicament |
Zongertinib |
| Institution |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
| Ville |
Montréal |
| Investigateur(trice) principal(e) |
Dr à venir
|
| Coordonnateur(trice) |
|
| Statut |
 Actif en recrutement |
| Critètes d'éligibilité |
- Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
- Patients ≥18 years old or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the Informed consent form (ICF).
-
Documented (previously established by local testing) Human epidermal growth factor receptor 2 (HER2) status of:
- HER2 overexpression/amplification
- Known activating HER2 mutations
- An archival (enrolment) tumour tissue sample must be submitted after inclusion of the patient to retrospectively confirm the HER2 status (enrolment tissue sample). If no archival tissue is available, this may be acceptable in exceptional cases after written agreement with the sponsor. Please note that sample must not be from an area irradiated prior to the biopsy.
- Patient with histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumour who has had at least one prior line of therapy for metastatic disease. In the opinion of the Investigator, patients must be unlikely to tolerate or derive clinically meaningful benefit from further standard of care therapy known to prolong survival.
Further inclusion criteria apply.
|
| Critètes d'exclusion |
- Diagnosis of HER2 mutant Non-small cell lung cancer (NSCLC)
-
Previous or concomitant malignancies other than the 1 treated in this trial within the previous 3 years except:
- effectively treated non-melanoma skin cancers
- effectively treated carcinoma in situ of the cervix
- effectively treated ductal carcinoma in situ of the breast
- localised prostate cancer on watchful waiting or active surveillance
- other effectively treated malignancy that is considered cured by local treatment.
- Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
- Not completely recovered from major surgery (major according to the investigator's assessment) performed prior to screening or planned within 6 months after screening, e.g. hip replacement Further exclusion criteria apply.
|
Groupe d'étude en oncologie du Québec